A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis
Public ClinicalTrials.gov record NCT02418845. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis
Study identification
- NCT ID
- NCT02418845
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Symbiomix Therapeutics
- Industry
- Enrollment
- 189 participants
Conditions and interventions
Conditions
Interventions
- SYM-1219 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 27, 2015
- Primary completion
- Oct 4, 2015
- Completion
- Dec 4, 2015
- Last update posted
- Oct 14, 2021
2015
United States locations
- U.S. sites
- 21
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35294 | — |
| Not listed | Jonesboro | Arkansas | 72401 | — |
| Not listed | San Diego | California | 92108 | — |
| Not listed | Colorado Springs | Colorado | 80910 | — |
| Not listed | Denver | Colorado | 80209 | — |
| Not listed | Leesburg | Florida | 34748 | — |
| Not listed | Miami | Florida | 33161 | — |
| Not listed | Wellington | Florida | 33414 | — |
| Not listed | Atlanta | Georgia | 30312 | — |
| Not listed | Baltimore | Maryland | 21224 | — |
| Not listed | Grand Rapids | Michigan | 49503 | — |
| Not listed | Plainsboro | New Jersey | 08536 | — |
| Not listed | New Bern | North Carolina | 28562 | — |
| Not listed | Columbus | Ohio | 73212 | — |
| Not listed | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | Philadelphia | Pennsylvania | 19114 | — |
| Not listed | Myrtle Beach | South Carolina | 29572 | — |
| Not listed | Corpus Christi | Texas | 78414 | — |
| Not listed | Houston | Texas | 77054 | — |
| Not listed | Virginia Beach | Virginia | 23456 | — |
| Not listed | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02418845, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2021 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02418845 live on ClinicalTrials.gov.